¼¼°èÀÇ À½¼º ±â¹Ý È£Èí±â °Ç°­ ¾Û ½ÃÀå
Audio-based Respiratory Health Apps
»óǰÄÚµå : 1798338
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 285 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,215,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,647,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ À½¼º ±â¹Ý È£Èí±â °Ç°­ ¾Û ½ÃÀåÀº 2030³â±îÁö 8,800¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 1,860¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ À½¼º ±â¹Ý È£Èí±â °Ç°­ ¾Û ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 29.6%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 8,800¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀΠõ½ÄÀº CAGR 24.8%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 3,120¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. COPD ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 34.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 510¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 38.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ À½¼º ±â¹Ý È£Èí±â °Ç°­ ¾Û ½ÃÀåÀº 2024³â¿¡ 510¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ 2024-2030³â¿¡ CAGR 38.0%·Î ÃßÀÌÇϸç, 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð 2,150¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 24.4%¿Í 26.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 24.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ À½¼º ±â¹Ý È£Èí±â °Ç°­ ¾Û ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

È£Èí±â °Ç°­ ¸ð´ÏÅ͸µÀÇ ´ÙÀ½ °³¹ßÁö´Â ¼Ò¸®°¡ µÉ °ÍÀΰ¡?

À½¼º ±â¹Ý È£Èí±â °Ç°­ ¾ÛÀº ¼Ò¸® ºÐ¼®À» Ȱ¿ëÇÏ¿© È£Èí °ü·Ã »óŸ¦ °¨ÁöÇÏ°í ¸ð´ÏÅ͸µÇÔÀ¸·Î½á ºñħ½ÀÀûÀ̰í Á¢±ÙÀÌ ¿ëÀÌÇϸç Áö´ÉÇü ÇコÄɾîÀÇ »õ·Î¿î ½Ã´ë¸¦ ¿­¾î°¡°í ÀÖ½À´Ï´Ù. ÀÌ ¾ÛµéÀº ½º¸¶Æ®ÆùÀÇ ¸¶ÀÌÅ©¿Í ¿ÜºÎ ¼¾¼­¸¦ ÀÌ¿ëÇØ ±âħ, õ¸íÀ½, È£Èí ÆÐÅÏ µîÀÇ È£ÈíÀ½À» ¼öÁýÇϰí, °í±Þ ¾Ë°í¸®Áò°ú ¸Ó½Å·¯´× ¸ðµ¨À» ÀÌ¿ëÇØ ºÐ¼®ÇÕ´Ï´Ù. Ŭ¸®´Ð¿¡¼­ ÁøÂûÀ» ¹Þ°Å³ª ºÎÇǰ¡ Å« Àåºñ°¡ ÇÊ¿äÇÑ ±âÁ¸ Áø´Ü Åø¿Í ´Þ¸®, ÀÌ ¾ÛÀº Áý¿¡¼­ ½Ç½Ã°£À¸·Î Æò°¡ÇÒ ¼ö ÀÖ´Â ±â´ÉÀ» Á¦°øÇÕ´Ï´Ù. ÀΰøÁö´ÉÀÇ µµ¿òÀ¸·Î ¼öÁýµÈ À½¼º µ¥ÀÌÅʹ õ½Ä, ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), Æó·Å, ±â°üÁö¿°, ½ÉÁö¾î COVID-19¿Í °°Àº È£Èí±â °¨¿°ÁõÀÇ Ãʱâ ¡ÈÄ¿Í °°Àº Áõ»ó ÁöÇ¥¿¡ ´ëÇØ Æò°¡µË´Ï´Ù. ÇöÀç, ÀϺΠ¿ëµµ´Â Àå±âÀûÀ¸·Î Áõ»óÀÇ ÁøÇàÀ» ÃßÀûÇÒ ¼ö ÀÖÀ¸¸ç, Àå±âÀûÀÎ °Ç°­ ¸ð´ÏÅ͸µÀ» °¡´ÉÇÏ°Ô Çϰí, »ç¿ëÀÚ³ª °£º´Àο¡°Ô ¾ÇÈ­ °¡´É¼º¿¡ ´ëÇØ °æ°íÇÏ´Â ¿ëµµµµ ÀÖ½À´Ï´Ù. ÃÖ±Ù µö·¯´×ÀÇ ¹ßÀüÀ¸·Î ÀÌ·¯ÇÑ ¾ÛÀÇ ¹Î°¨µµ¿Í ƯÀ̵µ°¡ Å©°Ô Çâ»óµÇ¾î ȯÀÚ¿Í ÀÇ»ç ¸ðµÎ¿¡°Ô ÀÇ»ç°áÁ¤ Áö¿ø Åø·Î¼­ ½Å·Úµµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸¹Àº Ç÷§ÆûÀÌ ÀüÀڰǰ­±â·Ï ¹× ¿ø°ÝÀÇ·á Æ÷ÅаúÀÇ ÅëÇÕÀ» Á¦°øÇÏ¿© ¿ø°Ý Áø´Ü°ú ÀÓ»ó Áø·áÀÇ ¿øÈ°ÇÑ ¿¬¼Ó¼ºÀ» Á¦°øÇÕ´Ï´Ù. ¼Ò¸® ±â¹Ý »ýüÀνÄ, ½º¸¶Æ®ÆùÀÇ À¯ºñÄõÅͽºÈ­, AI ±â¹Ý ºÐ¼®ÀÇ °áÇÕÀ¸·Î È£Èí±â ÁúȯÀ» ¹ß°ßÇÏ°í °ü¸®ÇÏ´Â ¹æ¹ýÀÌ ÀçÁ¤Àǵǰí ÀÖ½À´Ï´Ù. ƯÈ÷ È£Èí±â Àü¹®Àdzª Àü¹® °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇѵǾî ÀÖ´Â ³ó¾îÃÌ Áö¿ªÀ̳ª ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ª Áֹε鿡°Ô´Â Å« º¯È­ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¾ÛÀÌ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó ¼Ò¸®´Â Çö´ë È£Èí±â Ä¡·á¿¡¼­ Å« ÀáÀç·ÂÀ» °¡Áø Áß¿äÇϸ鼭µµ ÃæºÐÈ÷ Ȱ¿ëµÇÁö ¾ÊÀº ¹ÙÀÌ¿À¸¶Ä¿·Î Àνĵǰí ÀÖ½À´Ï´Ù.

ÇコÄÉ¾î ¸ðµ¨ÀÇ º¯È­·Î ÀÎÇØ µðÁöÅРȣÈí±â ÅøÀÇ °ø°£Àº ¾î¶»°Ô ¸¸µé¾îÁö°í Àִ°¡?

¼¼°è ÀÇ·á ¼­ºñ½º Á¦°øÀÇ ¿ªÇÐ °ü°èÀÇ º¯È­´Â À½¼º ±â¹Ý È£Èí±â °Ç°­ ¾ÛÀÇ Ã¤ÅÃÀ» °¡¼ÓÈ­ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è°¡ ȯÀÚ Áß½É Ä¡·á¿Í µðÁöÅÐ ¿ì¼±ÀÇ °Ç°­ ¼Ö·ç¼ÇÀ¸·Î ³ª¾Æ°¡°í ÀÖ´Â °¡¿îµ¥, Æí¸®¼º, ½Å¼Ó¼º, °æÁ¦¼ºÀ» Á¦°øÇÏ´Â ¿ø°Ý ¸ð´ÏÅ͸µ ÅøÀÇ °¡Ä¡´Â Á¡Á¡ ´õ Ä¿Áö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â ¸¸¼ºÁúȯ °ü¸®¿¡¼­ ƯÈ÷ µÎµå·¯Áö°Ô ³ªÅ¸³ª°í ÀÖÀ¸¸ç, ÀæÀº º´¿ø ¹æ¹®ÀÌ Áö¼ÓÀûÀÎ ÀçÅà Æò°¡·Î ´ëüµÇ°í ÀÖ½À´Ï´Ù. À½¼º È£Èí±â ¾ÛÀº ½Ç½Ã°£ ÃßÀû, Áõ»ó Á¶±â ¹ß°ß, ½ÅüÀû Á¢ÃËÀÌ ÇÊ¿ä ¾ø´Â °³ÀÎÈ­µÈ Çǵå¹éÀ» Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ Ãß¼¼¿¡ ¿Ïº®ÇÏ°Ô ºÎÇÕÇÕ´Ï´Ù. õ½ÄÀ̳ª COPD¿Í °°Àº Àå±âÀûÀΠȣÈí±â ÁúȯÀ» ¾Î°í Àִ ȯÀÚµéÀº Àç¹ß°ú º¹¾à ¼øÀÀµµ¸¦ °ü¸®Çϱâ À§ÇØ Áö¼ÓÀûÀÎ Áõ»ó ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ ¾ÛÀº ÀÇ»çÀÇ Áø·á¿Í Áø·á »çÀÌ¿¡ ÅëÁ¦·ÂÀ» À¯ÁöÇÒ ¼ö ÀÖ´Â ½Ç¿ëÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ °ø°ø ÀÇ·á ½Ã½ºÅÛ ¹× º¸Çè»çµéÀº ÀÌ·¯ÇÑ ±â¼úÀ» ÅëÇØ Á¶±â ¹ß°ß ¹× ¿¹¹æÀû Áúº´ °ü¸®¸¦ ÅëÇÑ ºñ¿ë Àý°¨ÀÇ ÀÌÁ¡À» ÀνÄÇϰí ÀÖ½À´Ï´Ù. º´¿ø°ú ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â º´¿ø ÀçÀÔ¿øÀ» ÁÙÀ̰í Ä¡·á ¼øÀÀµµ¸¦ ³ôÀ̱â À§ÇØ ÀÌ·¯ÇÑ ¾ÛÀ» ó¹æÇϰųª ±ÇÀåÇϱ⠽ÃÀÛÇß½À´Ï´Ù. ´Ù±¹¾î ÀÎÅÍÆäÀ̽º¿Í À½¼º °¡À̵åÀÇ ÅëÇÕÀ¸·Î »ç¿ëÀÚ Á¢±Ù¼ºÀÌ ´õ¿í Çâ»óµÇ¾î °í·ÉÀÚ³ª ¹®¸ÍÀڵ鵵 ½±°Ô »ç¿ëÇÒ ¼ö ÀÖ´Â ±â¼úÀÔ´Ï´Ù. ÆÒµ¥¹ÍÀº ¿ø°Ý Áø´Ü Åø¿¡ ´ëÇÑ ¼ö¿ä¸¦ °¡¼ÓÈ­½ÃÄ×°í, ±× ±â¼¼´Â ²ªÀÌÁö ¾Ê¾ÒÀ¸¸ç, Á¤ºÎ¿Í ÀÇ·á ±â°üÀº Àå±âÀûÀÎ Ä¡·á Àü·«ÀÇ ÀÏȯÀ¸·Î µðÁöÅРȣÈí±â ÇコÄɾî ÅøÀ» °è¼Ó ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°ø ¸ðµ¨ÀÌ ¿¹¹æ, Á¶±â °³ÀÔ, ÀçÅà ¼­ºñ½º Áß½ÉÀ¸·Î ÁøÈ­ÇÔ¿¡ µû¶ó À½¼º ±â¹Ý È£Èí±â ¾ÛÀÇ ¿ªÇÒÀº ÇコÄÉ¾î »ýŰ迡¼­ Á¡Á¡ ´õ Áß½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

ÀΰøÁö´É°ú ºòµ¥ÀÌÅͰ¡ È£ÈíÀ½ ºÐ¼®ÀÇ ¿µÇâ·ÂÀ» °­È­ÇÒ ¼ö Àִ°¡?

ÀΰøÁö´É°ú ºòµ¥ÀÌÅÍÀÇ À¶ÇÕÀº À½¼º ±â¹Ý È£Èí±â °Ç°­ ¾ÛÀÇ È¿°ú¿Í È®À强À» ȹ±âÀûÀ¸·Î ³ôÀÔ´Ï´Ù. ´Ù¾çÇÑ ¼Ó¼º°ú ÀÓ»óÀû ¹è°æÀ» °¡Áø »ç¿ëÀڷκÎÅÍ ¼öÁýÇÑ ´ë·®ÀÇ È£ÈíÀ½ µ¥ÀÌÅ͸¦ ºÐ¼®ÇÏ¿©, AI ¸ðµ¨Àº »ç¶÷ÀÇ ±Í³ª ±âÁ¸ Áø´Ü Åø·Î´Â °¨ÁöÇÒ ¼ö ¾ø¾ú´ø ÆÐÅÏÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÉÃþ ½Å°æ¸ÁÀº ƯÁ¤ È£Èí±â Áúȯ°ú °ü·ÃµÈ ¹Ì¹¦ÇÑ À½¼º ¸¶Ä¿¸¦ ÀνÄÇϵµ·Ï ÈÆ·ÃµÇ¾î Á¶±â¿¡ Á¤È®ÇÏ°Ô °¨ÁöÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸ðµ¨Àº ´õ ¸¹Àº µ¥ÀÌÅͰ¡ ½Ã½ºÅÛ¿¡ °ø±ÞµÊ¿¡ µû¶ó Áö¼ÓÀûÀ¸·Î °³¼±µÇ¾î °³º° ȯÀÚ ÇÁ·ÎÆÄÀÏ¿¡ ´ëÇÑ ¾ÛÀÇ ¹ÝÀÀ¼º°ú ÀûÀÀ¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Å¬¶ó¿ìµå ÄÄÇ»ÆÃ°ú ½Ç½Ã°£ µ¥ÀÌÅÍ ºÐ¼®À» ÅëÇØ ÀÌ·¯ÇÑ ¾ÛÀº ¼Ò¸®¸¦ Áï½Ã ó¸®ÇÏ°í »ç¿ëÀÚ ¹× ÀÇ·á Àü¹®°¡¿¡°Ô ºü¸¥ Çǵå¹éÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ °³¹ßÀÚµéÀº º´¿ø°úÀÇ Á¦ÈÞ ¹× ¿ÀǼҽº ÀÓ»ó ¸®Æ÷ÁöÅ丮¿¡¼­ °­·ÂÇÑ µ¥ÀÌÅͼ¼Æ®¸¦ ±¸ÃàÇϰí ÀÖÀ¸¸ç, ±ÔÁ¦ ´ç±¹ÀÇ °¨µ¶ ÇÏ¿¡ ¾Ë°í¸®ÁòÀ» °ËÁõÇÏ°í ¹Ì¼¼ Á¶Á¤ÇÏ´Â µ¥ Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ¿¹Ãø ¸ðµ¨¸µÀÌ Áß¿äÇÑ ±â´ÉÀ¸·Î ºÎ»óÇϰí ÀÖÀ¸¸ç, ÇöÀç¿Í °ú°ÅÀÇ À½¼º ÀÔ·Â, ȯ°æÀû ¿äÀÎ, »ç¿ëÀÚ°¡ º¸°íÇÑ Áõ»óÀ» ±â¹ÝÀ¸·Î ÀáÀçÀû ¾ÇÈ­¸¦ ¿¹ÃøÇÏ´Â ¾Ûµµ ÀÖ½À´Ï´Ù. À̸¦ ÅëÇØ Àû½Ã¿¡ ÀÇ·áÀû °³ÀÔÀÌ °¡´ÉÇØÁ® ÀÀ±Þ½ÇÀ» ¹æ¹®ÇÒ °¡´É¼ºÀÌ ³·¾ÆÁý´Ï´Ù. Áß¿äÇÑ °ÍÀº ¾Ïȣȭ, À͸íÈ­, HIPAA ¹× GDPR(EU °³ÀÎÁ¤º¸º¸È£±ÔÁ¤)°ú °°Àº ÀÇ·á µ¥ÀÌÅÍ ±ÔÁ¤ Áؼö¸¦ ÅëÇØ µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã¿Í º¸¾ÈÀ» ¿ì¼±½ÃÇϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. »ýŰ谡 ¼ºÀåÇÔ¿¡ µû¶ó ¿þ¾î·¯ºí ±â±â, µðÁöÅÐ ÈíÀÔ±â, °Ç°­ ¸ð´ÏÅ͸µ Ç÷§Æû°úÀÇ »óÈ£ ¿î¿ë¼ºÀÌ È®´ëµÇ¾î Á¾ÇÕÀûÀΠȣÈí±â °Ç°­ ÇÁ·¹ÀÓ¿öÅ©°¡ ±¸ÃàµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû ½Ã³ÊÁö È¿°ú·Î ÀÎÇØ À½¼º ±â¹Ý Áø´ÜÀÇ µµ´Þ ¹üÀ§¿Í ½Å·Ú¼ºÀÌ È®´ëµÇ¾î ¸ÂÃãÇü ÀÇ·á¿Í Áý´Ü°Ç°­°ü¸® ¸ðµÎ¿¡¼­ °­·ÂÇÑ Åø·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

¿À´Ã³¯ È£Èí±â °Ç°­ ¾ÛÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÇÙ½É ½ÃÀå µ¿·ÂÀº ¹«¾ùÀΰ¡?

À½¼º ±â¹Ý È£Èí±â °Ç°­ ¾Û ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú, ¼ÒºñÀÚ Çൿ, ÇコÄÉ¾î ¼ö¿ä, ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø µî ¿©·¯ °¡Áö »óÈ£ ¿¬°üµÈ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Áß¿äÇÑ ¿øµ¿·ÂÀº °íÀ½Áú ¸¶ÀÌÅ©¸¦ žÀçÇÑ ½º¸¶Æ®ÆùÀÇ º¸±ÞÀ¸·Î Ưº°ÇÑ Çϵå¿þ¾î ¾øÀ̵µ ÷´Ü À½Ç⠺м®ÀÌ °¡´ÉÇØÁ³½À´Ï´Ù´Â Á¡ÀÔ´Ï´Ù. µ¿½Ã¿¡ õ½Ä, COPD¿Í °°Àº ¸¸¼º È£Èí±â Áúȯ Áõ°¡·Î ÀÎÇØ ȯÀÚ°¡ ÀÚ½ÅÀÇ »óŸ¦ ´Éµ¿ÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ´Â Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ Åø¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ È£Èí±â °Ç°­¿¡ ´ëÇÑ ´ëÁßÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¼ÒºñÀÚ Çൿµµ Á¶±â ¹ß°ß ¹× ¿ø°Ý Ä¡·á ¼Ö·ç¼ÇÀ¸·Î ÀüȯµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ½ÅÈï ±¹°¡ÀÇ ÇコÄÉ¾î ½Ã½ºÅÛÀº ¸ð¹ÙÀÏ Áø´ÜÀ» Áö¿øÇÏ´Â µðÁöÅÐ Çコ ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ¾ÛÀÇ ¿ªÇÒÀÌ ´õ¿í ÀÔÁõµÇ°í ÀÖ½À´Ï´Ù. È£Èí±â Àü¹®ÀÇ¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇÑÀûÀÎ °³¹ßµµ»ó±¹¿¡¼­´Â ÀÌ·¯ÇÑ ¾ÛÀÌ Áö¿ª ÀÇ·áÁø°ú Çù·ÂÇÏ¿© ÃÖÀü¹æ Áø´Ü Åø·Î µµÀԵDZ⵵ ÇÕ´Ï´Ù. º¸Çè ÇÁ·Î¹ÙÀÌ´õ¿Í °¡Ä¡ ±â¹Ý ÄÉ¾î ¸ðµ¨µµ Àû½Ã¿¡ °³ÀÔÇÏ¿© ÀÔ¿øÀ» ¿¹¹æÇϰí Àå±âÀûÀÎ Ä¡·á ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ´Â ¼ö´ÜÀ¸·Î ¾Û »ç¿ëÀ» Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ±ÔÁ¦±â°üÀº ¼ÒÇÁÆ®¿þ¾î ±â¹Ý ÀÇ·á±â±â¿¡ ´ëÇÑ º¸´Ù ¸íÈ®ÇÑ ÇÁ·¹ÀÓ¿öÅ©¸¦ ±¸ÃàÇϱ⠽ÃÀÛÇßÀ¸¸ç, ´õ ¸¹Àº ±â¾÷ÀÌ ÀÓ»óÀûÀ¸·Î °ËÁõµÈ Á¦Ç°À¸·Î ½ÃÀå¿¡ ÁøÀÔÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. AI¿Í Ŭ¶ó¿ìµå ±â¼ú µµÀÔÀ¸·Î È®À强À» È®º¸ÇÏ´Â ÇÑÆí, ¿¬±¸±â°ü°úÀÇ Á¦ÈÞ¸¦ ÅëÇØ ÀÇ·áÀÇ ½Å·Ú¼º¿¡ ÇÊ¿äÇÑ ÀÓ»óÀû ±â¹ÝÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÈûÀÇ °áÇÕÀº Çõ½Å, Á¢±Ù¼º, ÀÓ»óÀû Çʿ伺ÀÌ °áÇÕµÈ °í¼ºÀå ȯ°æÀ» Á¶¼ºÇϰí, À½¼º ±â¹Ý È£Èí±â °Ç°­ ¾ÛÀº µðÁöÅÐ ÇコÄɾîÀÇ ÁøÈ­¸¦ À̲ô´Â Çõ½ÅÀû ¼Ö·ç¼ÇÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Áúȯ À¯Çü(õ½Ä, COPD, Æó·Å, ±âŸ Áúȯ), ¾ÖÇø®ÄÉÀ̼Ç(Áø´Ü ¾ÖÇø®ÄÉÀ̼Ç, ¸ð´ÏÅ͸µ ¾ÖÇø®ÄÉÀ̼Ç)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

°ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇÕ´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Audio-based Respiratory Health Apps Market to Reach US$88.0 Million by 2030

The global market for Audio-based Respiratory Health Apps estimated at US$18.6 Million in the year 2024, is expected to reach US$88.0 Million by 2030, growing at a CAGR of 29.6% over the analysis period 2024-2030. Asthma, one of the segments analyzed in the report, is expected to record a 24.8% CAGR and reach US$31.2 Million by the end of the analysis period. Growth in the COPD segment is estimated at 34.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Million While China is Forecast to Grow at 38.0% CAGR

The Audio-based Respiratory Health Apps market in the U.S. is estimated at US$5.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$21.5 Million by the year 2030 trailing a CAGR of 38.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 24.4% and 26.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 24.9% CAGR.

Global Audio-based Respiratory Health Apps Market - Key Trends & Drivers Summarized

Is Sound Becoming the Next Frontier in Respiratory Health Monitoring?

Audio-based respiratory health apps are ushering in a new era of non-invasive, accessible, and intelligent healthcare by leveraging sound analysis to detect and monitor breathing-related conditions. These apps utilize smartphone microphones or external sensors to capture respiratory sounds such as coughs, wheezes, and breathing patterns, which are then analyzed using advanced algorithms and machine learning models. Unlike traditional diagnostic tools that require in-clinic visits or bulky equipment, these apps offer real-time assessment capabilities from the comfort of a user's home. With the help of artificial intelligence, the collected audio data is evaluated for indicators of conditions such as asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and even early signs of respiratory infections like COVID-19. Some applications are now capable of tracking symptom progression over time, enabling long-term health monitoring and alerting users or caregivers about potential deteriorations. Recent advancements in deep learning have significantly improved the sensitivity and specificity of these apps, making them more reliable as decision-support tools for both patients and physicians. Moreover, many platforms offer integration with electronic health records and telemedicine portals, creating seamless continuity between remote diagnostics and clinical care. This combination of sound-based biometrics, smartphone ubiquity, and AI-driven analytics is redefining how respiratory illnesses are detected and managed. It is particularly transformative for populations in rural or underserved areas where access to pulmonologists or specialized testing may be limited. As these apps continue to evolve, sound is being recognized as a vital, underutilized biomarker that holds enormous potential in modern respiratory care.

How Are Shifting Healthcare Models Creating Space for Digital Respiratory Tools?

The changing dynamics of global healthcare delivery are playing a pivotal role in accelerating the adoption of audio-based respiratory health apps. As the world moves toward patient-centric care and digital-first health solutions, remote monitoring tools that offer convenience, speed, and affordability are becoming increasingly valuable. The shift is particularly pronounced in chronic disease management, where frequent clinic visits are being replaced by continuous home-based assessments. Audio respiratory apps align perfectly with this trend by offering real-time tracking, early symptom detection, and personalized feedback without the need for physical contact. Patients with long-term respiratory conditions such as asthma or COPD often require consistent symptom monitoring to manage flare-ups and medication adherence. These apps provide a practical solution for maintaining control between physician appointments. Additionally, public health systems and insurers are recognizing the cost-saving benefits of early detection and proactive disease management enabled by these technologies. Hospitals and healthcare providers are beginning to prescribe or recommend such apps to reduce hospital readmissions and improve treatment compliance. The integration of multilingual interfaces and voice-guided instructions further enhances user accessibility, making the technology inclusive for elderly populations and those with low literacy levels. The pandemic accelerated demand for remote diagnostic tools, and the momentum has not slowed, with governments and health organizations continuing to promote digital respiratory health tools as part of long-term care strategies. As care delivery models evolve to emphasize prevention, early intervention, and home-based services, the role of audio-based respiratory apps is becoming increasingly central to the healthcare ecosystem.

Can Artificial Intelligence and Big Data Enhance the Impact of Respiratory Sound Analytics?

The convergence of artificial intelligence and big data is dramatically enhancing the effectiveness and scalability of audio-based respiratory health apps. By analyzing large volumes of respiratory sound data collected from users across various demographics and clinical backgrounds, AI models can identify patterns that would be imperceptible to the human ear or traditional diagnostic tools. Deep neural networks are trained to recognize subtle audio markers associated with specific respiratory disorders, enabling early and accurate detection. These models continuously improve over time as more data is fed into the system, making the apps more responsive and adaptive to individual patient profiles. Moreover, cloud computing and real-time data analytics allow these apps to process sounds instantly and deliver rapid feedback to users and healthcare professionals. Developers are also building robust datasets from hospital partnerships and open-source clinical repositories, which are being used to validate and fine-tune their algorithms under regulatory scrutiny. Predictive modeling is emerging as a key feature, with some apps forecasting potential exacerbations based on current and historical audio input, environmental factors, and user-reported symptoms. This allows for timely medical intervention and reduces the likelihood of emergency room visits. Importantly, data privacy and security are being prioritized through the implementation of encryption, anonymization, and compliance with health data regulations such as HIPAA and GDPR. As the ecosystem grows, interoperability with wearable devices, digital inhalers, and health monitoring platforms is expanding, creating a comprehensive respiratory health framework. These technological synergies are amplifying the reach and reliability of audio-based diagnostics, positioning them as powerful tools in both personalized medicine and population health management.

What Are the Core Market Forces Propelling the Growth of Respiratory Health Apps Today?

The growth in the audio-based respiratory health apps market is driven by several interconnected factors spanning technology, consumer behavior, healthcare needs, and regulatory support. A significant driver is the widespread adoption of smartphones equipped with high-fidelity microphones, making it feasible to conduct advanced sound analysis without specialized hardware. Concurrently, the global rise in chronic respiratory diseases such as asthma and COPD is increasing demand for continuous monitoring tools that can empower patients to manage their condition proactively. The increased public awareness of respiratory health, fueled by the COVID-19 pandemic, has also shifted consumer behavior toward early detection and remote care solutions. Healthcare systems, particularly in developed economies, are investing in digital health infrastructure that supports mobile diagnostics, further validating the role of these apps. In developing regions, where access to respiratory specialists is limited, these apps are being deployed as front-line diagnostic tools, sometimes in conjunction with community health workers. Insurance providers and value-based care models are also encouraging their use as a means of reducing long-term treatment costs by preventing hospitalizations through timely intervention. Meanwhile, regulatory bodies are beginning to establish clearer frameworks for software-based medical devices, allowing more companies to enter the market with clinically validated products. The inclusion of AI and cloud technologies ensures scalability, while partnerships with research institutions provide the clinical grounding needed for medical credibility. These combined forces are fostering a high-growth environment where innovation, access, and clinical necessity converge, making audio-based respiratory health apps a transformative solution in the ongoing evolution of digital healthcare.

SCOPE OF STUDY:

The report analyzes the Audio-based Respiratory Health Apps market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Asthma, COPD, Pneumonia, Others Diseases); Application (Diagnostic Application, Monitoring Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â